Quick Answer
AN2 Therapeutics, Inc. reported Operating Income Loss of -$38.11 million for the year ending 2025.
- AN2 Therapeutics, Inc. showed an increase of +32.9% in Operating Income Loss from 2024 to 2025.
- This data is from AN2 Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$2.05 million | Q2 2021: -$5.00 million | Q3 2021: -$6.93 million | Q1 2022: -$7.68 million | Q2 2022: -$10.33 million | Q3 2022: -$11.77 million | Q1 2023: -$16.04 million | Q2 2023: -$16.60 million | Q3 2023: -$18.18 million | Q1 2024: -$18.30 million | Q2 2024: -$15.88 million | Q3 2024: -$14.01 million | Q1 2025: -$11.54 million | Q2 2025: -$7.22 million | Q3 2025: -$10.04 million.
- Over the full 5 years of available data (2021 to 2025), AN2 Therapeutics, Inc.'s Operating Income Loss has declined by 76.6%.
- Historical annual values: Fiscal year 2025: -$38.11 million | Fiscal year 2024: -$56.79 million | Fiscal year 2023: -$69.64 million | Fiscal year 2022: -$42.26 million | Fiscal year 2021: -$21.57 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: